Fluorescein Angiography for Age-Related Macular Degeneration
Understanding Fluorescein Angiography
Fluorescein angiography is a diagnostic imaging procedure that maps the blood vessels in your retina and the layer beneath it called the choroid. During the test, a retina specialist or technician injects a special dye called fluorescein into a vein, usually in your arm. As the dye travels through the blood vessels of your eye, a camera takes rapid photographs. These photographs show how blood flows through the retina and whether any vessels are leaking or growing abnormally.
The test takes about 10 to 15 minutes from start to finish. The resulting images give your retina specialist a detailed, real-time view of vascular health in the back of your eye. No other imaging test provides exactly the same information about blood vessel leakage.
The fluorescein dye glows when exposed to a specific wavelength of blue light. As the dye passes through retinal blood vessels, the camera captures this glow at different time points. Healthy blood vessels contain the dye within their walls. Abnormal blood vessels lack the tight junctions that normally prevent leakage, so the dye seeps out into surrounding tissue.
Retina specialists look at the images in phases. Early-phase images show the dye arriving in the retinal arteries and filling the smaller vessels. Late-phase images, taken several minutes later, reveal whether dye has leaked and pooled outside the vessels. This leakage pattern is critical for identifying choroidal neovascularization (abnormal new blood vessels growing beneath the retina), the hallmark of wet AMD.
Optical coherence tomography (OCT) is another common imaging test used for AMD. OCT creates cross-sectional images of the retina, showing its layers in fine detail. It is excellent for detecting fluid buildup and measuring retinal thickness. However, OCT does not directly show whether blood vessels are leaking or identify the specific source of that leakage.
Fluorescein angiography and OCT provide complementary information. Both tests are highly effective for evaluating AMD (Retina Today, 2014). While OCT has become more commonly used for routine monitoring because it is noninvasive, FA remains essential for classifying the type of AMD, especially the wet form.
Why Fluorescein Angiography Matters in AMD
Age-related macular degeneration exists in two main forms: dry AMD and wet AMD. Dry AMD involves the gradual breakdown of light-sensitive cells in the macula. Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood. Fluorescein angiography is the most important test for classifying AMD into its subtypes, especially the wet form.
The distinction matters because the two forms require different management approaches. Wet AMD demands prompt treatment with injections to prevent rapid vision loss. Accurately identifying which subtype is present, and which pattern of abnormal blood vessels exists, directly influences the treatment plan.
Choroidal neovascularization (CNV) is the growth of new, fragile blood vessels from the choroid layer into or beneath the retina. These vessels are the primary cause of severe vision loss in wet AMD. During fluorescein angiography, CNV appears as an area of hyperfluorescence (bright glowing). This brightness starts early in the test and grows in both size and intensity over subsequent images.
This expanding pattern of brightness is a key diagnostic feature. It distinguishes active CNV from areas of atrophy, which also appear bright early but do not expand beyond their original borders. This distinction is critical for choosing the right treatment approach.
The specific angiographic pattern of CNV helps determine how a retina specialist will treat the condition. Fluorescein angiography reveals whether the abnormal vessels are located directly under the center of the macula or off to the side. It also shows the size and boundaries of the leaking area. These details inform medication choice and injection frequency.
Fluorescein angiography is also required to reassess the diagnosis in patients who do not respond to a given treatment. If a patient continues to lose vision despite ongoing injections, FA can reveal whether a different problem is contributing to the vision loss.
OCT angiography (OCTA) is a newer, noninvasive imaging technique that can visualize blood flow without dye injection. While promising, OCTA has recognized limitations. It has limited ability to image blood flow beneath pigment epithelial detachments (areas where the retinal pigment layer has separated from its base). In certain complex cases, only fluorescein angiography can provide the complete diagnostic picture.
Both OCT and FA are recognized as valid monitoring tools for AMD treatment response (CMS, NCA Decision Memo). This reflects the complementary roles of these technologies rather than the replacement of one by the other.
Who Needs Fluorescein Angiography
Fluorescein angiography is indicated for any patient with AMD who experiences vision loss, metamorphopsia (distorted or wavy vision), or a new scotoma (a blind or dark spot in the visual field) when CNV is suspected. These symptoms may signal the onset of wet AMD and require urgent evaluation. Clinical signs that raise suspicion include elevation of the retinal pigment epithelium, bleeding beneath the retina, and exudate (fatty deposits from leaking vessels).
Not all patients with wet AMD notice symptoms right away. Those at high risk for developing CNV should be carefully examined for these changes, even without new complaints.
An estimated 18.34 million Americans have early AMD, and 1.49 million have the late-stage form of the disease (Prevent Blindness, VEHSS Data). Among people aged 80 and older, approximately 3 in 10 have early AMD and approximately 1 in 10 have the late form. AMD is the leading cause of significant vision loss in people over age 50 in developed countries.
Risk factors for AMD progression include advancing age, smoking, family history of AMD, and certain genetic factors. A retina specialist may recommend fluorescein angiography for patients who show signs of progression from dry to wet AMD.
When a patient receiving anti-VEGF injections does not show the expected improvement, fluorescein angiography can help uncover the reason. The test may reveal persistent or recurrent CNV, a different subtype of CNV, or a separate condition contributing to vision changes. This information allows the retina specialist to adjust the treatment plan accordingly.
The Patient Experience
Your retina specialist or their team will review your medical history and ask about any allergies, particularly to dyes or iodine. Dilating eye drops will be placed in your eyes to widen the pupils, allowing a better view of the retina. Dilation typically takes about 20 to 30 minutes to reach full effect. You will be asked to sit in front of the angiography camera, which looks similar to other eye examination equipment.
It is helpful to bring sunglasses, as your eyes will remain dilated and sensitive to light for several hours after the procedure. You may also want to arrange for someone to drive you home.
A technician will place a small needle into a vein in your arm or hand, similar to a standard blood draw. The fluorescein dye is then injected through this needle. Within seconds, the dye reaches the blood vessels in your eyes. The camera takes a rapid series of photographs as the dye flows through. You may be asked to look in different directions so the photographer can capture all areas of the retina.
Most patients feel a brief, warm sensation as the dye is injected. The test itself is not painful, though the initial needle stick may cause mild discomfort. The entire imaging process generally takes about 10 minutes. Additional photos are sometimes taken at the 5 to 10 minute mark to capture late-phase images.
After the procedure, your skin may appear slightly yellow for a few hours. Your urine will turn bright orange or yellow for one to two days. This is normal and simply means your body is clearing the dye. You should drink plenty of water to help flush the fluorescein from your system.
Most people can return to normal activities the same day, aside from driving if their pupils are still dilated. Your retina specialist will review the images and discuss the results with you, often at the same visit or at a follow-up appointment.
Fluorescein angiography is generally a safe procedure. The most common side effects are mild and include temporary nausea, which occurs in a small percentage of patients. Rarely, some patients may experience an allergic reaction to the dye, ranging from hives to more serious reactions.
Before the test, inform your retina specialist about any known allergies or previous reactions to fluorescein dye. The medical team will have emergency equipment available as a precaution.
How Fluorescein Angiography Connects to AMD Treatment
Before starting treatment for wet AMD, a retina specialist uses fluorescein angiography to establish a baseline picture of the disease. This initial angiogram documents the location, size, and type of choroidal neovascularization present. It serves as a reference point for measuring whether treatment is working over time.
The baseline FA also helps the retina specialist choose among available anti-VEGF medications. Currently approved anti-VEGF drugs for wet AMD include Eylea (aflibercept), Lucentis (ranibizumab), Vabysmo (faricimab), and Beovu (brolucizumab). Avastin (bevacizumab), which is FDA-approved for cancer treatment, is also widely used off-label for wet AMD. The angiographic findings may influence which medication is best suited for a particular patient.
While OCT has become the primary monitoring tool for most patients receiving anti-VEGF injections, fluorescein angiography still plays a valuable role in certain situations. OCT is noninvasive, quick, and effective at detecting fluid in or beneath the retina. For routine follow-up visits, OCT is often sufficient to determine whether the disease is stable or active.
However, when OCT findings are unclear or when a patient is not improving as expected, fluorescein angiography provides additional information. It can reveal the source and extent of persistent leakage, identify new areas of CNV, or confirm that treatment has successfully closed the abnormal vessels.
Fluorescein angiography is not needed at every visit. For many patients with wet AMD, the test may be performed at the time of initial diagnosis and repeated only when there is a clinical reason. A retina specialist may order a repeat FA if there is a sudden change in vision or if the disease seems to progress despite treatment.
As imaging technology continues to advance, fluorescein angiography remains a foundational diagnostic tool. Its ability to directly visualize dye leakage from abnormal blood vessels gives it a unique role that complementary technologies like OCT and OCTA have not fully replaced.
When to See a Retina Specialist
Certain symptoms related to AMD require immediate attention. If you experience a sudden increase in floaters, flashes of light, a curtain or shadow over your vision, or sudden vision loss in one eye, see a retina specialist or go to the emergency room immediately. These symptoms may indicate a serious change in your condition that needs prompt evaluation.
If you have been diagnosed with dry AMD and notice new or worsening distortion of straight lines, a dark or empty area in your central vision, or difficulty reading even with your glasses, contact a retina specialist promptly. Metamorphopsia, or the perception that straight lines appear wavy, may indicate the onset of choroidal neovascularization.
Early detection of wet AMD through timely fluorescein angiography and other diagnostic testing gives anti-VEGF treatment the best chance of preserving your remaining vision.
If you are over age 50 and have risk factors for AMD, regular eye examinations are important. An optometrist or ophthalmologist can screen for early signs of AMD and refer you to a retina specialist if needed. Patients already diagnosed with AMD in one eye are at higher risk for developing the condition in the other eye.
Using an Amsler grid at home, a simple tool with a grid of straight lines, can help you monitor your central vision between appointments. Any new distortion, missing areas, or waviness on the grid should be reported to your retina specialist right away.
Questions and Answers
The test involves a needle stick in a vein in your arm, which may cause brief, mild discomfort similar to a blood draw. The imaging portion is not painful. Some patients experience a temporary warm sensation or mild nausea when the dye is injected, but these effects typically pass quickly. Your medical team will monitor you throughout the procedure.
Most patients with AMD do not need fluorescein angiography at every visit. The test is typically performed at the time of diagnosis and repeated when there is a specific clinical reason. Examples include a change in symptoms, an unclear OCT result, or a lack of response to treatment. Your retina specialist will determine the appropriate timing based on your individual situation.
Fluorescein angiography can identify features of both dry and wet AMD, but it is most valuable for diagnosing and classifying wet AMD. In dry AMD, the angiographic appearance remains stable throughout the phases of the test. Areas of atrophy appear as consistent bright spots that do not expand. In wet AMD, the test reveals the characteristic expanding leakage pattern from choroidal neovascularization. For monitoring dry AMD, OCT is typically the preferred imaging tool.
Fluorescein angiography is generally safe for most patients. Mild side effects like nausea and temporary skin discoloration are the most common. Allergic reactions are rare but possible, ranging from mild hives to more serious events. Patients with a known allergy to fluorescein dye should inform their retina specialist before the test. Pregnant patients should discuss the risks and benefits with their doctor, as the safety of fluorescein dye during pregnancy has not been fully established.
OCT has not fully replaced fluorescein angiography, though it has taken over many routine monitoring functions. OCT is noninvasive and effective at detecting retinal fluid and measuring thickness changes. However, fluorescein angiography provides unique information about blood vessel leakage and the specific subtype of choroidal neovascularization. The two tests serve complementary roles, and most retina specialists use both as part of a comprehensive approach to AMD care.